ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: ATN-161 may stop the growth of tumor cells by blocking blood flow to the tumor.
Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Giving ATN-161
together with carboplatin may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of ATN-161 when
given together with carboplatin and to see how well they work in treating patients with
recurrent malignant glioma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)